If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVersarien Regulatory News (VRS)

  • This share is currently suspended. It was suspended at a price of 0.01
  • There is currently no data for VRS

South American Graphinks Agreements

14 Mar 2024 07:00

RNS Number : 7801G
Versarien PLC
14 March 2024
 

14 March 2024

Versarien Plc

("Versarien", the "Company" or the "Group")

South American Graphinks? Agreements

Versarien Plc (AIM: VRS), the advanced materials engineering group, announces that the Company has, in line with its stated strategy to monetise intellectual property through licensing, entered into a manufacturing licence agreement and a know-how licence and technical assistance agreement (together the "Agreements") with Montana Química LTDA ("Montana"). Montana is a Brazilian headquartered multinational business focused on the production and sale of paints, wood preservatives and other wood finishing products including stains and varnishes.  The Agreements cover the use of certain of the Company's proprietary graphene and related material dispersions and formulations (Graphinks?) in products to be manufactured and sold by Montana in South America, together with Versarien providing further additional know-how, technical assistance and training to Montana.

Further Details on the Agreements

Under the terms of the Agreements, Versarien has granted a licence to Montana (the "Licence"), for an initial period of five years, to use certain intellectual property and know-how owned by the Company in their business in South America. Montana will pay Versarien initial fees of £50,000 in March 2024 in consideration of the know-how and technical assistance, including training, to be provided. Once Montana commences manufacturing under the Agreement, a further payment of £25,000 will be due to the Company, together with an amount equal to 5% of the total sales revenue earned from products manufactured using Versarien's intellectual property and know-how ("Royalty"), subject to minimum Royalty payments of £25,000 per annum.

Dr Stephen Hodge, CEO of Versarien, commented: "The Agreements with Montana are in line with Versarien's strategy to be a manufacturing-light business in the UK and licence our patents, know-how and other intellectual property to key partners. We are very pleased to be partnering with Montana, a leading business in its markets in South America, and look forward to collaborating closely with them as they bring products enhanced by Versarien's technology to the market."

Andreas von Salis, CEO of Montana, commented: "The Agreements with Versarien give Montana the opportunity to capitalise on the growing markets for graphene in Brazil with the intention to utilise graphene in application areas such as paints, coatings and lubricants."

For further information please contact:

 

Versarien

Stephen Hodge, Chief Executive Officer

Chris Leigh, Chief Financial Officer

 

c/o IFC

SP Angel Corporate Finance (Nominated Adviser and Broker)

Matthew Johnson, Adam Cowl

 

+44 (0)20 3470 0470

 

IFC Advisory Limited (Financial PR and Investor Relations)

Tim Metcalfe, Zach Cohen

+44 (0) 20 3934 6630

 

About Versarien Graphinks?

 

Versarien's Graphinks? are graphene and related material (GRM) inks and dispersions that bring multi-functionality (high electrical and thermal conductivity, fire retardation, UV protection, etc.), produced via a high pressure homogenisation process that offers high yield and uniform size distribution. Versarien have 'standard' Graphinks? for different deposition methods from inkjet to screen printing and developmental formulations with different nanomaterials and solvent combinations.

 

For further information please see: http://www.versarien.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRGPUWUWUPCPGW
Date   Source Headline
9th Feb 20267:00 amRNSCancellation - Versarien Plc
6th Jan 20261:34 pmRNSAppointment of Administrators
19th Dec 20254:36 pmRNSUpdate on NOIA
19th Dec 20254:36 pmRNSUpdate on NOIA
15th Dec 20253:53 pmRNSUpdate on the Disposal of AAC Cyroma Limited
12th Dec 20257:00 amRNSUpdate on NOIA and Change of Registered Office
1st Dec 20257:30 amRNSSuspension - Versarien plc
1st Dec 20257:00 amRNSIntention to Appoint Administrators, Suspension
26th Nov 20257:00 amRNSUpdate - Proposed Disposal of the Company's Assets
31st Oct 20258:48 amRNSProposed Disposal of the Company’s Assets
29th Sep 20252:32 pmRNSCorporate Update
10th Sep 20251:00 pmRNSCorporate Update
29th Aug 20252:19 pmRNSCorporate Update
21st Aug 20257:00 amRNSStrategic Investment and Joint Venture Update
11th Aug 20257:00 amRNSCorporate Update
5th Aug 202511:03 amRNSHolding(s) in Company
29th Jul 20257:00 amRNSCorporate Update
22nd Jul 202510:55 amRNSSettlement of Legal Claims
4th Jul 20257:00 amRNS-RSouth American Polygrene™ Themoplastics Agreements
30th Jun 20253:03 pmRNSInterim Results
19th Jun 20252:34 pmRNSBuilding for Humanity – Contract Update
4th Jun 202511:49 amRNSHolding(s) in Company
2nd Jun 20252:03 pmRNSHolding(s) in Company
30th May 202510:19 amRNSHolding(s) in Company
30th May 20257:00 amRNSTotal Voting Rights
29th May 20253:29 pmRNSHolding(s) in Company
29th May 202510:20 amRNSHolding(s) in Company
27th May 202511:59 amRNSHolding(s) in Company
27th May 202511:02 amRNSHolding(s) in Company
23rd May 20259:38 amRNSHolding(s) in Company
22nd May 202511:56 amRNSHolding(s) in Company
21st May 202510:58 amRNSHolding(s) in Company
20th May 202511:11 amRNSHolding(s) in Company
14th May 20257:00 amRNSPlacing to raise £425,000
2nd May 202511:00 amRNSUpdate on Legal Claims
28th Apr 20251:04 pmRNSResult of AGM
27th Mar 20257:00 amRNSAudited Results for year ended 30 September 2024
24th Mar 202511:24 amRNSResult of General Meeting
10th Mar 20257:00 amRNS-RGraphinks™ supply agreement with Montana Química
5th Mar 20257:00 amRNSNotice of General Meeting
3rd Mar 20257:00 amRNSCompletion of Sale of Korean Assets
28th Feb 20257:00 amRNSTotal Voting Rights
27th Feb 20257:00 amRNSInnovate UK Loan Deed of Variation
10th Feb 20258:35 amRNSHolding(s) in Company
28th Jan 20252:36 pmRNSPlacing to raise £246k
30th Dec 202412:00 pmRNSUpdate on Sale of Korean Assets
13th Dec 20242:58 pmRNSHolding(s) in Company
13th Dec 202411:50 amRNSHolding(s) in Company
13th Dec 202410:11 amRNSHolding(s) in Company
13th Dec 20247:00 amRNS€804,000 Grant Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.